The stock will trade on pipeline catalysts rather than current financials. Monitor SONATA-HCM topline data in Q1 2027 and ZYNQUISTA NDA resubmission in Q4 2026 as the primary value drivers. The $190.6M cash position provides runway through these events, reducing near-term financing risk.
Drugs in focus
LXRX drug pipeline →ZYNQUISTA
◆ Mixed Named in this press release- Impact
- Phase
- Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
- Time to market
- Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
- Next catalyst
- None dated
What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $2.36entry
- T+1 · 3mo ago +4.66%α +4.05% · $2.47
- T+5 · 3mo ago −0.85%α −2.06% · $2.34
- T+20 · 3mo ago −4.24%α −4.84% · $2.26
- T+60 · 18d ago −39.83%α −38.16% · $1.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27.6M Novo Nordisk licensing milestone, and a net loss of $31.8M ($0.07/share) vs net income of $3.3M a year ago. The key catalysts are the completion of SONATA-HCM enrollment (topline Q1 2027) and ZYNQUISTA NDA resubmission expected Q4 2026, with $190.6M cash providing runway through these events.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $0.7M vs $28.9M in Q2 2025 (included $27.6M licensing milestone from Novo Nordisk)
- Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025
- SONATA-HCM Phase 3 enrollment completed on time, substantially exceeding 500-patient target; topline results expected Q1 2027
- ZYNQUISTA NDA resubmission for type 1 diabetes anticipated Q4 2026
- Cash and investments $190.6M as of June 30, 2026, up from $125.2M at year-end 2025
- Entered $100M loan facility with Hercules Capital in May 2026; initial $55M tranche funded
Financial Impact
Revenue decline of $28.2M YoY driven by absence of one-time licensing milestone; net loss widened by $35.0M YoY
Risk Factors
- SONATA-HCM Phase 3 failure or mixed results would be a major setback
- ZYNQUISTA NDA resubmission could face delays or additional FDA requirements
- Cash burn rate of ~$16M/quarter may require additional financing before catalysts mature
- INPEFA commercial revenue remains minimal ($0.7M/quarter) with unclear path to profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340161 |
Track record
16 reports on LXRX
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Viewing Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers